Back to 
JPMorgan Chase & Co.
JPMorgan Chase & Co.
ENGN
3 quarters
Position history for JPMorgan Chase & Co.'s holdings in enGene Therapeutics Inc.
As of its Q1 2026 13F, JPMorgan Chase held 1,977 shares of ENGN (enGene Therapeutics), worth $12,218. JPMorgan Chase's 13F filings listed ENGN from Q4 2025 to Q1 2026, 2 quarterly filings.
Final Value
$0
Final Shares
0
Total Value Change
-$23,604
Total Shares Change
-2,614
Quarter-by-Quarter History
Other major holders of ENGN: Adage Capital Partners GP, L.L.C., Janus Henderson Group Ltd.